Celecoxib
- Generic Name
- Celecoxib
- Brand Names
- Celebrex, Elyxyb, Seglentis
- Drug Type
- Small Molecule
- Chemical Formula
- C17H14F3N3O2S
- CAS Number
- 169590-42-5
- Unique Ingredient Identifier
- JCX84Q7J1L
- Background
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon...
- Indication
Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.
...
- Associated Conditions
- Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain
- Associated Therapies
- -
Pre vs Post Block in Total Knee Arthroplasty (TKA)
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 84
- Registration Number
- NCT05974501
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Multimodal Pain Package vs. Regular Formulation for Pain Management in Ambulatory Spinal Surgery
- Conditions
- Interventions
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 100
- Registration Number
- NCT05965492
- Locations
- 🇺🇸
university of Miami, Miami, Florida, United States
🇺🇸University of Miami, Miami, Florida, United States
Chinese Spondyloarthritis Inception Cohort (CESPIC)
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Southwest Hospital, China
- Target Recruit Count
- 1000
- Registration Number
- NCT05960864
Efficacy and Safety of SKCPT in Patients With Knee Osteoarthritis: Phase III Clinical Trial
- First Posted Date
- 2023-07-05
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- SK Chemicals Co., Ltd.
- Target Recruit Count
- 278
- Registration Number
- NCT05930080
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT05756166
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Serplulimab Combined with CAPEOX + Celecoxib As Neoadjuvant Treatment for Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-16
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 50
- Registration Number
- NCT05731726
- Locations
- 🇨🇳
Second Affiliated Hospital School of Medicine Zhejiang University, Hangzhou, Zhejiang, China
INflammation-based Stratification for Immune-Targeted Augmentation in Major Depressive Disorder
- Conditions
- Interventions
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Universiteit Antwerpen
- Target Recruit Count
- 240
- Registration Number
- NCT05644301
- Locations
- 🇧🇪
UPC Duffel, Duffel, Antwerpen, Belgium
🇧🇪UZ Brussel, Brussels, Belgium
🇧🇪Katholiek Universiteit Leuven Campus Kortenberg, Leuven, Belgium
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Food Effect and DDI of Ascending Doses of the MEK Inhibitor Zapnometinib
- Conditions
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Atriva Therapeutics GmbH
- Target Recruit Count
- 96
- Registration Number
- NCT05555823
- Locations
- 🇩🇪
Atriva study site, Neu-Ulm, Germany
Opioid-Free Pain Protocol After Shoulder Arthroplasty
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Henry Ford Health System
- Target Recruit Count
- 80
- Registration Number
- NCT05488847
- Locations
- 🇺🇸
Henry Ford Health, Detroit, Michigan, United States
Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers
- Conditions
- Interventions
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 59
- Registration Number
- NCT05438303
- Locations
- 🇺🇸
Research Site, Berlin, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.